We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Roche Group’s rheumatoid arthritis drug Actemra (tocilizumab) was found to reduce mortality and improve outcomes for high-risk COVID-19 patients, according to researchers from the UK’s Imperial College London. Read More
As some of the world’s largest drugmakers gear up to manufacture and distribute COVID-19 vaccines, a relatively tiny competitor, Massachusetts-based Moderna, faces some unique challenges. Read More
Researchers at the University of Oxford expect to report results from their phase 3 trials of AstraZeneca’s (AZ) COVID-19 vaccine candidate, AZD1222, before Christmas, the study’s leader said. Read More
The FDA has not been fully transparent about its Emergency Use Authorizations (EUAs) for COVID-19 treatments as it “does not uniformly disclose” its scientific review of safety and effectiveness data for EUAs, as it does for approvals for new drugs and biologics,” the Government Accountability Office said in a new report to Congress. Read More
Eli Lilly and South Korea’s Samsung Biologics have forged a long-term partnership to expand the Indianapolis, Ind.-based drugmaker’s supply of COVID-19 neutralizing antibody treatments, amid concerns about shortages as coronavirus cases spike globally. Read More
Both Moderna’s and Pfizer’s COVID-19 vaccine candidates could receive Emergency Use Authorization (EUA) in less than a month and be ready for rollout in a matter of weeks, HHS Secretary Alex Azar said Wednesday, giving hope that high-risk patients could receive a vaccine before the year ends. Read More
To take the test, the user swirls a self-collected swab in a vial that is placed into the test unit. Users can then read the test results after approximately 30 minutes directly from a light-up display. Read More
Moderna has reached a deal with the British government to supply an initial five million doses of its coronavirus vaccine, mRNA-1273, in spring of next year. Read More
German drugmaker CureVac is scaling up its manufacturing capability in the European Union and plans to ship 300 million doses of its COVID-19 vaccine, CVnCoV, across the world next year and 600 million doses in 2022. Read More
FDA Commissioner Stephen Hahn pledged yesterday that the agency will publicly post detailed explanations of all Emergency Use Authorization (EUA) decisions, including all COVID-19 vaccine candidates now in the pipeline. Read More
The European Medicines Agency (EMA) has launched a rolling review of Moderna’s vaccine candidate mRNA-1273, on the heels of the Cambridge, Mass., drugmaker’s announcement that the vaccine demonstrated 94.5 percent efficacy in early results from a phase 3 trial. Read More